US State Department To Debut Freedom Program With Bitcoin

The U.S. State Department is launching a program that includes Bitcoin as a way to advance digital freedom worldwide. 

Named the Freedom Tech Excellence Program, the initiative will see the State Department work with the Bitcoin Policy Institute, data-analytics firm Palantir Technologies, defense technology company Anduril Industries, and the Victims of Communism Memorial Foundation on issues including online surveillance, encryption, AI governance, and protecting free expression online.

According to the program’s stated goals, participants will focus on five priority areas: First Amendment and free expression protections in the digital age; countering unlawful digital surveillance and online scams; privacy-enhancing technologies such as strong encryption and VPNs; responsible governance of emerging technologies including AI; and safeguarding children and other users online.

The inclusion of the Bitcoin Policy Institute signals that the Department views Bitcoin and blockchain technology as tools relevant to circumventing censorship and financial surveillance in authoritarian states — a theme the organization has long championed in its advocacy work.

The FTEP will operate through limited-term assignments, placing private sector personnel inside the State Department on temporary embeds tasked with shaping diplomatic efforts around specific digital freedom issues. 

President Trump campaigned on a ticket to help the crypto space and since taking office, his government has taken a more pro-crypto approach to both regulating and including elements of the space in his administration. 

In March 2025, for example, President Trump signed an executive order establishing a Strategic Bitcoin Reserve and a separate U.S. Digital Asset Stockpile, capitalized with roughly 200,000 Bitcoin already held by the government through criminal and civil forfeiture. 

The order framed Bitcoin alongside strategic reserves the U.S. maintains for materials like gold, petroleum, and pharmaceuticals, treating it as a scarce national asset rather than merely a speculative one.